Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatoid Arthritis

Self-Monitoring of RA Treatment May Lead to Fewer Office Visits

Reuters Staff  |  September 5, 2015

NEW YORK (Reuters Health)—Self-monitoring of methotrexate therapy may curb healthcare utilization in rheumatoid arthritis (RA) and psoriatic arthritis, according to a new trial. The study indicates “that this novel model of care led to significant reductions in outpatient visits to the (clinical nurse specialist) and a reduction in visits to the GP, while maintaining the…

Alcohol Use Complicates Chronic Disease Management in Teens

Will Boggs, MD  |  September 1, 2015

NEW YORK (Reuters Health)—High school students with chronic medical conditions who drink alcohol are more likely than their nondrinking peers to forget or skip taking their medications, according to an online survey. “I was surprised to see such a clear association between alcohol use and medication nonadherence—a finding which really brings home the need to…

Can We Get Closer to a Cure for RA?

Marc Feldmann & Ravinder N. Maini  |  September 1, 2015

Despite new therapeutics, progress for RA patients has virtually stalled over the past 10 years. In this article, the authors discuss many options to advance to a cure and the evidence for them, including the combination of low-dose methotrexate and anti-TNF; targeting angiogenesis and tissue damage pathways directly; antigen-specific therapy; potential combination of TNF and IL17 blockade; and targeting inhibitory receptors and regulatory T cells.

Early, Aggressive Therapy for RA May Result in Cost Savings Long Term

Lara C. Pullen, PhD  |  August 31, 2015

By considering the long-term damage from early, aggressive rheumatoid arthritis, researchers in the UK were able to develop a model demonstrating the long-term cost effectiveness of more aggressive combination therapies v. short-term treatments…

Depression May Increase Risk of Cardiovascular Disease for RA Patients

Kathryn Doyle  |  August 22, 2015

(Reuters Health)—Mental health problems, like anxiety and depression, may partly explain why people with rheumatoid arthritis have an increased risk of cardiovascular disease, according to a new study. Researchers linked anger, anxiety, depressive symptoms, job stress and low social support to increasing risk of hardening of the arteries, or atherosclerosis, for people with rheumatoid arthritis…

Oral & Gut Microbiomes Altered in Rheumatoid Arthritis Patients

Reuters Staff  |  August 20, 2015

NEW YORK (Reuters Health)—Patients with rheumatoid arthritis (RA) have alterations in their oral and gut microbiomes that partially normalize with treatment, according to results from a metagenome-wide association study. The microbiota influence metabolic and immune homeostasis, and microbial triggers have been postulated in RA, but little is known about the oral and gut microbiomes of…

RA Diagnosis Uses Lab Tests, Clinical Insight to Rule Out Lyme

Charles Radis, DO  |  August 18, 2015

What struck me first as I walked by the exam room where Lynn P. sat was the swelling in her fingers and wrists. The bloated hands rested unnaturally on her thighs, palms up, fingers slightly flexed. Her strawberry-blond curls were offset by a high-neck, loose-fitting, burgundy sweater. Her pale skin matched her trim slacks. She had…

Biosimilar Drugs for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2015

Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection…

EULAR 2015: RA Research Shows Imperfect Guidelines, Suggests Strategies with Biologics

Thomas R. Collins  |  August 17, 2015

ROME, Italy—Even with classification criteria that have been updated and refined over time, rheumatoid arthritis is still a diagnosis that ultimately has to be made with clinical judgment, said Ronald van Vollenhoven, MD, PhD, professor of medicine and chief of clinical therapy research in inflammatory diseases at the Karolinska University in Sweden. His remarks came…

Similar RA Outcomes with Abatacept & Tocilizumab

Will Boggs, MD  |  August 17, 2015

NEW YORK (Reuters Health)—Clinical outcomes of rheumatoid arthritis (RA) are similar with abatacept and tocilizumab treatment, but the factors that predict efficacy differ for the two agents. “The recommendations for RA treatment from the U.S. and EU describe the use of abatacept and tocilizumab as first-line biologics along with anti-TNF (anti-tumor necrosis factor) inhibitors,” Dr….

  • « Previous Page
  • 1
  • …
  • 43
  • 44
  • 45
  • 46
  • 47
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences